- Report
- April 2025
- 50 Pages
Global
From €2512EUR$2,650USD£2,098GBP
- Report
- April 2025
- 50 Pages
Global
From €2512EUR$2,650USD£2,098GBP
Phendimetrazine is an anti-obesity drug used to treat overweight and obesity. It is a sympathomimetic amine, similar to an amphetamine, and works by suppressing appetite and increasing energy levels. It is usually prescribed as a short-term treatment for obesity, and is often used in combination with diet and exercise. Phendimetrazine is available in both immediate-release and extended-release formulations. The extended-release formulation is designed to provide a more gradual release of the drug over a longer period of time.
Phendimetrazine is a popular anti-obesity drug, and is widely prescribed by physicians. It is generally well-tolerated, and has been shown to be effective in helping patients lose weight. However, it is not recommended for long-term use, as it can be habit-forming and may cause side effects such as insomnia, dry mouth, and increased heart rate.
The Phendimetrazine market is highly competitive, with many companies offering generic and branded versions of the drug. Some of the major players in the market include Mylan, Teva Pharmaceuticals, Actavis, and Sandoz. Show Less Read more